Skip to content

Balangu syrup on Gastroesophageal Reflux

Effect of Balangu syrup in patients with Gastroesophageal Reflux

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2016120331205N1
Enrollment
84
Registered
2017-01-10
Start date
2016-12-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroesophageal reflux. Gastro-oesophageal reflux disease

Interventions

Intervention group: effect of Balangu syrup on reflux symptoms on 84 patients once a day for a month.
Treatment - Drugs
Intervention group: effect of Balangu syrup on reflux symptoms on 84 patients once a day for a month

Sponsors

Shahed University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
17 Years to 74 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria:Based on the clinical symptoms of reflux in patients with gastroesophageal reflux;Heartburn; Gastroesophageal reflux from the stomach into the esophagus and mouth; patients who are unresponsive to conventional therapies. Exclusion criteria:There are warning signs such as weight loss, anemia, severe vomiting and consuming food that has not been endoscopy and mechanical causes of food stuck in it is not rejected; Peptic strictures; complications of reflux; Barrett's esophagus approved in previous endoscopy patients; esophagitis with non-reflux causes; Systemic diseases (liver disease, kidney disease, uncontrolled diabetes); pregnancy; Anti-reflux surgery; Anti-reflux drugs

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Clinical symptoms of reflux (heartburn or Gastroesophageal reflux from the stomach into the esophagus and mouth). Timepoint: 4 weeks. Method of measurement: The questionnaire is based on studies conducted by Lai et al (2006).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohsen Naseri

Traditional Iranian Medicine Clinical Trial

r.jafari.hajati@gmail.comnaserishahed@gmail.com+98 21 6646 4320

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026